Ayalon D, Ben-David M, Wohl R, Jaffe R, Vagman I, Eckstein N, Limor R, Comaru-Schally A M, Schally A V
Timsit Institute of Reproductive Endocrinology, Tel Aviv University School of Medicine, Israel.
Gynecol Endocrinol. 1988 Dec;2(4):319-30. doi: 10.3109/09513598809107655.
Seventeen patients with polycystic ovarian disease (PCOD) and evidence of mild or severe ovarian hyperstimulation syndrome (OHSS) during therapy with CC/hCG, FSH/hCG or hMG/hCG were treated with D-Trp6-LHRH until medical gonadectomy was attained. Under the suppressive therapy with the GnRH agonist (GnRHa) ovulation was induced with FSH/hCG. In 15 out of 17 patients, ovulatory cycles were obtained with this new modality of treatment. Seven patients conceived (3 viable pregnancies and 4 early abortions) after the 1st treatment cycle. Fourteen of the 17 patients demonstrated symptoms of mild OHSS which did not require hospitalization. Only 1 patient developed severe OHSS after the combined treatment. Our results suggest that therapy with GnRHa, especially in its delayed release formulation, is effective for the prevention of severe ovarian hyperstimulation in PCOD patients undergoing treatment with menotropins for the induction of ovulation.
17例多囊卵巢疾病（PCOD）患者在使用克罗米芬/人绒毛膜促性腺激素（CC/hCG）、促卵泡激素/人绒毛膜促性腺激素（FSH/hCG）或人绝经期促性腺激素/人绒毛膜促性腺激素（hMG/hCG）治疗期间出现轻度或重度卵巢过度刺激综合征（OHSS）迹象，这些患者接受了D-色氨酸6-促黄体生成素释放激素（D-Trp6-LHRH）治疗，直至达到药物性卵巢切除状态。在促性腺激素释放激素激动剂（GnRHa）的抑制治疗下，使用FSH/hCG诱导排卵。在17例患者中的15例中，通过这种新的治疗方式获得了排卵周期。7例患者在第1个治疗周期后受孕（3例活产妊娠和4例早期流产）。17例患者中有14例表现出轻度OHSS症状，无需住院治疗。联合治疗后只有1例患者发生了重度OHSS。我们的结果表明，GnRHa治疗，尤其是其缓释制剂，对于预防接受促性腺激素治疗以诱导排卵的PCOD患者发生重度卵巢过度刺激是有效的。
